Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT

David J Beard,1* Loretta J Davies,1
Jonathan A Cook,2 Graeme MacLennan,2
Andrew Price,1 Seamus Kent,3 Jemma Hudson,2
Andrew Carr,1 Jose Leal,3 Helen Campbell,3
Ray Fitzpatrick,3 Nigel Arden,1 David Murray1 and
Marion K Campbell2 on behalf of the TOPKAT Study Group†

1Nuffield Department of Orthopaedics, University of Oxford, Oxford, UK
2Health Services Research Unit, University of Aberdeen, Aberdeen, UK
3Department of Public Health, University of Oxford, Oxford, UK

*Corresponding author david.beard@ndorms.ox.ac.uk
†The full membership of the TOPKAT Study Group is listed in the Acknowledgements.

Declared competing interests of authors: Jonathan A Cook reports grants from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme during the conduct of the study and was a member of the NIHR HTA Efficient Trial Designs Board between 2014 and 2016. He was also a member of the NIHR HTA End of Life Care and Add-on Studies Board during these years and a member of a NIHR Research for Patient Benefit programme regional advisory committee (South Central/South East & Central) between 2015 and 2019. Graeme MacLennan reports grants from the NIHR HTA programme during the conduct of the study. Ray Fitzpatrick reports membership of the HTA Prioritisation Group and the HTA National Stakeholder Advisory Group during the conduct of the study (October 2015 to present). Nigel Arden reports grants from Merck & Co. (Kenilworth, NJ, USA), personal fees from Flexion Therapeutics (Burlington, MA, USA), Freshfields Bruckhaus Deringer (London, UK), Merck & Co., Regeneron Pharmaceuticals (Tarrytown, NY, USA) and Eli Lilly and Company (Indianapolis, IN, USA)/Pfizer Inc. (New York, NY, USA) outside the submitted work. Andrew Price reports personal fees from Zimmer Biomet (Warsaw, IN, USA), DePuy (Warsaw, IN, USA) and Smith & Nephew (Watford, UK); he also reports grants from NIHR and Arthritis Research UK outside the submitted work. David Murray reports grants and personal fees from Zimmer Biomet outside the submitted work; in addition, he has various patents relating to knee replacement with royalties paid. Marion K Campbell reports grants from NIHR during the conduct of the study.

Published April 2020
DOI: 10.3310/hta24200
Scientific summary

The TOPKAT RCT
Health Technology Assessment 2020; Vol. 24: No. 20
DOI: 10.3310/hta24200

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Knee replacement for treatment of osteoarthritis of the knee is an effective and common procedure, with > 700,000 procedures performed each year in the USA and 1,076,778 procedures performed in the UK between 2003 and 2017. There are two main surgical options to replace the diseased areas of late-stage medial compartment osteoarthritis of the knee. Some surgeons consider the treatment of choice to be a total knee replacement, whereas others feel that it is best to replace just the damaged component of the knee with a partial or unicompartmental knee replacement. Such variation in decision-making for patients who have similar pathology is well recognised, with high levels of disagreement between surgeons for implant choice. The best treatment option remains uncertain, with little evidence to date to prove the clinical effectiveness and cost-effectiveness of either treatment management option.

The literature to date has consisted of individual cohort studies, indirect comparisons and retrospective studies, which often examine very specific aspects of knee replacement surgery (e.g. complications and the ability to kneel). To our knowledge, no large, well-powered, multicentre randomised controlled trial has been undertaken to directly compare partial knee replacement with total knee replacement. Joint registry data have shown a trend towards total knee replacement having better implant survival, but other studies are characterised by low-level evidence, consensus and peer influence. To provide robust and unbiased estimates of the relative benefits and harms of the procedures and assess cost-effectiveness, a large randomised controlled trial was required.

The trial was required to evaluate clinical effectiveness at the 5-year follow-up, a time point that is considered the minimum for arthroplasty evaluation; however, early reoperation and complications were also considered key to this comparison. Evaluation of 5-year revision was an important aspect of the trial, as it has been implied that partial knee replacement is more technically demanding than total knee replacement, a feature that may contribute to the increased incidence of complications/failure seen in the larger national registry data.

Objectives

The main objective for TOPKAT (Total or Partial Knee Arthroplasty Trial) was to assess the clinical effectiveness and cost-effectiveness of total knee replacement compared with partial (unicompartmental) knee replacement in patients with medial compartment osteoarthritis of the knee in a formal randomised comparison. The primary outcome measure was a patient-reported outcome measure, the Oxford Knee Score. A second research question involved failure of each type of operation in terms of reoperation, revision and a composite outcome measure of the Oxford Knee Score and reoperation. Other objectives included investigation and comparison of post-operation activity levels, complications and patient satisfaction. The findings are intended to guide surgical decision-making for patients, surgeons and health-care providers.

Methods

The study was a multicentre randomised controlled trial of patients who were randomised to either partial knee replacement or total knee replacement. The target sample size was 500 patients. The trial had a combined equipoise/expertise-based approach to randomisation. The expertise-based randomisation enabled surgeons not in equipoise to participate in the trial by working in pairs, each
providing the operation type that they felt was appropriate (as ‘experts’). Patients were randomised to the partial knee replacement or the total knee replacement surgeon in the pair. The ‘in equipoise’-based randomisation involved surgeons who had sufficient experience of both operation types and who were willing to perform either operation. Minimum levels of expertise were ensured, with all surgeons having had appropriate training in both operations and having performed a minimum of 10 partial knee replacement and 10 total knee replacement procedures. Patients were not blinded to their intervention.

Outcome measures
The trial was designed and powered to examine both self-reported outcome (at 5 years) and complication/reoperation differences between the groups at 5 years. The primary outcome measure was the Oxford Knee Score, a well-validated patient-reported outcome questionnaire that is specifically developed to assess function and pain after knee replacement surgery.

Of the secondary outcome measures recorded, the frequency of complications and failure of operation were considered particularly important to assess differences between the two interventions. Complications were assessed by distinguishing those that required re-admission and reoperation (revision or other related procedure). Failure of intervention was assessed using a prespecified composite outcome assessment (combination of reoperation and poor outcome as defined by Oxford Knee Score); poor outcome was ascribed if the Oxford Knee Score did not improve by > 4 points.

Other secondary measures were:

- The American Knee Society Score at 2 months and 1 year post surgery and 5 years post randomisation. Both clinical assessment and function were recorded.
- The University of California Los Angeles Activity Score at 2 months post surgery and 1–5 years post randomisation.
- The High Activity Arthroplasty Score at 2 months post surgery and 1–5 years post randomisation.
- The EuroQol-5 Dimensions at 2 months (post surgery) and 1–5 years post randomisation.
- Self-reported anchor-type questions about satisfaction, transition in relation to problems, overall health, transition in relation to overall health and reflection on whether or not they would still have the operation again.
- Surgical (intra- and post-operative) complications.
- Health-care and patient resource use (e.g. length of hospital stay at time of operation, 2 months post surgery and 1–5 years post randomisation).
- Reoperation rate following knee replacement surgery, including revision.
- Composite outcome assessment – failure of intervention defined as reoperation (including revision) and/or poor outcome indicated by Oxford Knee Score.
- Oxford Knee Score-Activity and Participation Questionnaire adjunct score to the Oxford Knee Score at years 4 and 5 post randomisation.
- Radiographic imaging of the knee preoperatively, immediately postoperatively and at 5 years post randomisation.

Participants and setting
A total of 528 patients were recruited from 27 UK NHS sites (68 surgeons) from January 2010 to September 2013. Participants had to have osteoarthritis of the medial compartment of the knee and satisfy general requirements for a medial partial knee replacement. Potential participants were identified in outpatient and at pre-assessment clinics by participating surgeons, or were identified from local databases. Participants signed a consent form during their screening visit and were free to withdraw from the study at any time.

Study interventions
The trial was pragmatic and compared partial knee replacement with total knee replacement using any brand or model of implant in common use. For this reason, surgeons were free to use the implant
of their own or their institution’s choice. A total knee replacement involved all surfaces of the knee being replaced. The procedure involved excising both diseased and normal femoral condyles, the tibial plateau and often the patella, as well as removing or releasing some of the ligaments. The artificial implant could be cemented in position if desired. A partial knee replacement involved only the diseased area of the joint being replaced. The healthy compartments of the knee and ligaments were retained and artificial implants were inserted in place of the diseased area.

**Recruitment and consent**
The preoperative (baseline) assessment included the Oxford Knee Score, activity level, health-care resource use and the American Knee Society Score. Routine preoperative X-rays were also performed. Randomisation (which utilised minimisation) used a web-based randomisation service at the Centre for Healthcare Randomised Trials, Health Services Research Unit, University of Aberdeen. The minimisation algorithm incorporated sex, age (<50, 50–70 or >70 years) and baseline Oxford Knee Score band (<14, 15–21 or ≥22) and ‘delivery unit’. A delivery unit was either an ‘equipoise surgeon’ or a pair of ‘expertise surgeons’ who had complementary expertise.

Operative details were recorded in theatre and routine post-operative X-rays were conducted. Patients then attended a clinic for the American Knee Society Score assessment at 2 months, 1 year and 5 years post operation. All other outcomes were collected using postal questionnaires. In cases where there was >12 weeks between randomisation and the operation date (owing to the waiting list), an additional Oxford Knee Score was administered at the clinical assessment 1 year post surgery.

**Statistics and analysis**
The sample size was calculated on the Oxford Knee Score and the reoperation rate. Detection of a change in reoperation rate of 7% between groups (from 5% to 12%) at 80% power and using a significance level of $p < 0.05$ (two-sided) required a sample size of 250 patients per group. A total of 250 patients per group also provided 90% power to detect a reoperation increase to 14% (difference of 9%). For the primary end point at 5 years, a sample size of 500 patients (250 in each group) was also required to identify clinically significant differences in Oxford Knee Score. This sample size provided 90% (and 80%) power to detect a mean difference of 3.0 (and 2.0) Oxford Knee Score points at 5% (two-sided) significance level using a standard deviation of 10.0 points.

Statistical analysis was primarily on an ‘intention-to-treat’ basis and participants were analysed according to their allocated group using all available participant data. Low frequency event data, such as reoperation and revision, were also analysed on an ‘as-treated’ basis to avoid misrepresentation because of lack of compliance to the allocated intervention (crossover). The Oxford Knee Scores for total knee replacement and partial knee replacement were compared using multiple linear regression analysis adjusted for minimisation factors and baseline Oxford Knee Score and using robust cluster variance to account for surgery delivery unit. Any differential impact of expertise versus equipoise delivery of the intervention on treatment effect was explored using an interaction effect. Prespecified subgroup analyses of sex, Oxford Knee Score band and age were explored using treatment-by-subgroup interactions. Secondary outcomes were analysed using the same approach as the primary outcome within a generalised linear models framework. Binary variables (including complications and reoperations at 5 years) and length of hospital stay (counted in full days) were compared using a Poisson regression to estimate risk ratios adjusted for minimisation covariates with robust cluster variance to account for surgery delivery unit. Statistical significance was judged at the two-sided 5% level and treatment effect estimates are presented with corresponding 95% confidence intervals. Missing effectiveness data were not imputed in the principal analysis. For Oxford Knee Score and EuroQol-5 Dimensions, three-level version, at 1 and 5 years, sensitivity analyses explored the impact of imputing worse case (0 and –0.594, respectively) across both groups and each of the randomised groups in turn.

For the health economics analysis, the total costs and quality-adjusted life-years for all 528 participants were estimated from the date of recruitment until the earliest of death, withdrawal from study or the
end of follow-up at 5 years. Both costs and quality-adjusted life-years were discounted at 3.5% per year. Mean total health-care costs and quality-adjusted life-years were estimated using separate linear regression models controlling for treatment allocation, age group, sex and baseline Oxford Knee Score band, following the main clinical analysis. For quality-adjusted life-years, we also controlled for EuroQol-5 Dimensions score at baseline. Incremental cost-effectiveness ratios were calculated by dividing the mean cost difference between partial knee replacement and total knee replacement by the mean quality-adjusted life-year difference. The joint uncertainty around incremental total costs and quality-adjusted life-years (i.e. the difference between partial knee replacement and total knee replacement) was also investigated. Sensitivity analyses, using a complete-case analysis, were also provided.

Results

In total, 528 patients were randomised and baseline variables between groups were well balanced. A representative range of implants was used in the trial when compared with UK National Joint Registry data. The follow-up primary outcome response rate was 88%. At 5-year follow-up, both operations had good outcomes. Patients in both groups had superior outcome to their preoperative baseline status. The changes in Oxford Knee Score following partial knee replacement and total knee replacement intervention were substantial (mean Oxford Knee Score change greater than 18 points for both procedures).

There was no evidence of difference between groups in the primary outcome of mean Oxford Knee Score at the 5-year time point (difference 1.04, 95% confidence interval –0.42 to 2.50). Although there was no evidence of difference in the primary outcome between groups at the 5-year time point in a cross-sectional and marginal analysis, a post hoc area under the curve analysis of the Oxford Knee Score for the duration of the study did show significant benefit in favour of partial knee replacement over total knee replacement. More patients achieved higher outcome scores after partial knee replacement than other total knee replacement. It should be noted that this difference across operation types was similar and smaller than the minimal clinically important difference of the score [mean 36.6 (standard deviation 8.3), mean 35.1 (standard deviation 9.1), respectively].

Secondary outcome measures showed consistent patterns of benefit for partial knee replacement, although some differences were small and non-significant: Oxford Knee Score-Activity and Participation Questionnaire difference 1.00 (95% confidence interval –3.50 to 5.50), University of California Los Angeles difference 0.17 (95% confidence interval –0.009 to 0.43), EuroQol-5 Dimensions visual analogue score difference 4.0 (95% confidence interval 1.36 to 6.67) and patient satisfaction (82% for partial knee replacement and 77% for total knee replacement). The EuroQol-5 Dimensions visual analogue scale global health instrument revealed significant differences in favour of partial knee replacement. Both transition (problems better now than before operation: partial knee replacement 95% and total knee replacement 90%) and reflection (Would you have the operation again?: partial knee replacement 91% and total knee replacement 84%) were significantly better for partial knee replacement, although both of these variables are potentially susceptible to bias owing to the lack of blinding.

The frequency of reoperation (including revision) by the treatment received was similar in both groups: 22 out of 245 partial knee replacement patients and 28 out of 269 total knee replacement patients. Revision rates at 5 years were 10 out of 245 for partial knee replacement and 8 out of 269 for total knee replacement. There were 28 ‘failures’ of partial knee replacement, as defined by the composite outcome, and 38 ‘failures’ of total knee replacement.

The health economic evaluation found partial knee replacement to be more effective (0.240 quality-adjusted life-years, 95% confidence interval 0.046 to 0.434 quality-adjusted life-years) and to cost less than total knee replacement (£910, 95% confidence interval £317 to £1503) over the 5 years of follow-up. This finding was a result of slightly better outcome (as measured by the EuroQol-5 Dimensions), lower partial knee replacement surgery costs and lower follow-up health-care costs. If cost of the implant devices
is assumed to be equal partial knee replacement remains less costly and more effective than total knee replacement.

Trials are susceptible to interpretation bias, especially if differences are small and investigators have prior preference for a particular intervention. A summary set of blinded results was sent to a group of entirely independent and unconnected assessors (trial experts and surgeons) to help interpret the results and impact of the trial in an unbiased manner.

There are many strengths of this study. To our knowledge, it is the largest randomised controlled trial to date in the world with the longest and most comprehensive follow-up. The study was well powered and the follow-up rates were very high (88%). The pragmatic design, the large number of sites and surgeons and the wide variety of implants used provided high external validity. The inclusion of an expertise component allowed high surgeon participation, regardless of their personal equipoise. Employment of independent assessors to interpret the results helped to neutralise personal and institutional bias.

Limitations included lack of patient blinding and some non-compliance with allocated interventions, although this had little effect on the overall results. Surgeons providing partial knee replacement were all experienced with this procedure.

**Conclusions**

Both total knee replacement and partial knee replacement are effective, offer similar clinical outcomes and have similar reoperation and complication rates. The revision rates for partial knee replacement in this trial were, however, substantially lower than those found in other studies and in non-randomised cohort data. The reasons require further investigation, one being that TOPKAT involved surgeons who were already experienced at implanting partial knee replacement, leading to a lower revision rate. Several secondary patient-reported measures were significantly higher for partial knee replacement, and partial knee replacement was more cost-effective than total knee replacement at 5 years. Although total knee replacement is safe and adequate, on the basis of the combined clinical and cost-effectiveness results, partial knee replacement shows some advantages over total knee replacement for patients with late-stage medial compartment osteoarthritis.

**Clinical impact**

Both total knee replacement and partial knee replacement remain treatment options for medial compartment arthritis of the knee. This study has shown that partial knee replacement offers some advantages over total knee replacement. However, the operation should be carried out by those with sufficient experience and expertise, and surgical training programmes should address any unmet need identified by this study.

**Future work**

Further follow-up is required to assess the longer-term stability of these findings over time (10-year follow-up started in March 2020 and will be completed by October 2023). Further research is also required into the effect of experience and the disparity between trial and cohort data.
**Trial registration**

This trial is registered as ISRCTN03013488 and ClinicalTrials.gov NCT01352247.

**Funding**

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment*; Vol. 24, No. 20. See the NIHR Journals Library website for further project information.
HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 08/14/08. The contractual start date was in January 2010. The draft report began editorial review in February 2019 and was accepted for publication in October 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by Beard et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

**Professor John Powell**  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Senior Clinical Researcher, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

**Professor Andrée Le May**  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

**Professor Matthias Beck**  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Eugenia Cronin**  Senior Scientific Advisor, Wessex Institute, UK

**Dr Peter Davidson**  Consultant Advisor, Wessex Institute, University of Southampton, UK

**Ms Tara Lamont**  Director, NIHR Dissemination Centre, UK

**Dr Catriona McDaid**  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meads**  Professor of Wellbeing Research, University of Winchester, UK

**Professor John Norrie**  Chair in Medical Statistics, University of Edinburgh, UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

**Professor Jonathan Ross**  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Ken Stein**  Professor of Public Health, University of Exeter Medical School, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

**Professor Martin Underwood**  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** journals.library@nihr.ac.uk